New drug duo targets tough pancreatic cancer in phase 2 trial
NCT ID NCT07114315
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs, AK130 and AK112, can help control advanced pancreatic cancer. About 160 adults whose cancer has worsened after up to two prior treatments will receive the combination or AK112 alone. The goal is to see if the treatment shrinks tumors or slows disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact
-
Zhongshan Hospital Affiliated to Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
Contact